Impel Pharmaceuticals, Inc.

Follow-on public offerings (FOPOs) have become increasingly difficult to execute in the current financial market climate with public biopharmaceutical company valuations plummeting, so many drug devel

Cost-cutting has become the norm for biopharmaceutical companies in 2023 as drug developers struggle to raise capital for ongoing research and development programs, never mind bringing in new funding

Having an approved and marketed drug is not enough to keep a biopharmaceutical company alive in the current financing environment in which stock prices are down and public offerings are not viable fun

The ongoing reckoning among biopharmaceutical companies that are running out of cash and unable to raise new funds – either because of a lack of near-term upcoming milestones or missed milestones – is